Merck, Inc.
🇵🇭Philippines
Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705)
Phase 2
Terminated
- Conditions
- Panic Disorder
- Interventions
- Behavioral: Cognitive-behavioral therapyDrug: Org 25935Drug: Placebo
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 46
- Registration Number
- NCT00725725
Investigation of 9 Consecutive Remicade Infusions in Ankylosing Spondylitis in Austria (Study P04044)(COMPLETED)
Completed
- Conditions
- Spondylitis, Ankylosing
- Interventions
- Biological: Infliximab
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2015-09-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 358
- Registration Number
- NCT00725543
Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427)
Completed
- Conditions
- Hepatitis CHepatitis C, Chronic
- Interventions
- Biological: PegIntron (peginterferon alfa-2b; SCH 54031)Drug: Rebetol (ribavirin; SCH 18908)
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2015-02-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1146
- Registration Number
- NCT00724854
Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001)
Phase 2
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: MK-8435 (Org 25935) 4-8 mgDrug: MK-8435 (Org 25935) 12-16 mgDrug: Placebo
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 215
- Registration Number
- NCT00725075
Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)
Completed
- Conditions
- Hepatitis C, ChronicHepatitis C
- Interventions
- Biological: PegIntron (Peginterferon alfa-2b)Drug: Rebetol (Ribavirin)
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 294
- Registration Number
- NCT00725205
Real Life Dosing of Remicade for Rheumatoid Arthritis in Austria Monitored Over 9 Infusions (Study P03756)(COMPLETED)
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: Infliximab
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2015-09-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 516
- Registration Number
- NCT00725621
Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED)
Completed
- Conditions
- Hepatitis C, ChronicHepatitis C
- Interventions
- Biological: peginterferon alfa-2bDrug: ribavirin
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 901
- Registration Number
- NCT00723632
Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
Completed
- Conditions
- AstrocytomaGlioblastomaGlioma
- Interventions
- Drug: TemozolomideRadiation: Radiotherapy
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 682
- Registration Number
- NCT00723827
Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Biological: Peginterferon alfa-2b (SCH 54031)Drug: Ribavirin (SCH 18908)
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2015-09-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 442
- Registration Number
- NCT00724373
Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)
Completed
- Conditions
- Hepatitis CHepatitis C, Chronic
- Interventions
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2015-09-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1128
- Registration Number
- NCT00724451
© Copyright 2025. All Rights Reserved by MedPath